Multicenter study on the treatment of cerebralcare granule for patients with mild and moderate vascular cognitive impairment

Objective To explore the improvement of cognitive impairment in patients with mild and moderate vascular cognitive impairment(VCI) treated with cerebralcare granule (CG) and basic treatment. Methods From October in 2014 to December in 2016 year, 143 cases of VCI patients were admitted from six hospitals in some areas of Hebei Province as the research objects, and divided into CG treatment group (experimental group, n=98) and conventional treatment group (control group, n=66). Three months and six months after treatment, the score of mental state examination (MMSE), the Montreal cognitive assessment scale (MoCA) and the daily living capacity scale(ADL) of the two groups were compared after 3 and 6 moths of treatment. Results ①The total score of MMSE in the experimental group was higher than that of the control group for six months after treatment, and the difference was statistically significant ((23.76±4.02) vs (21.52±5.13), P 0.05). Conclusion CG can improve cognitive function in mild to moderate VCI patients, mainly in visual space/execution function, calculation ability and orientation ability, and with the extension of treatment time, the curative effect is more obvious. Key words: Cerebralcare granule; Vascular cognitive impairment; MMSE; MoCA